Valneva: net loss sharply reduced in 2024

(CercleFinance.com) - Valneva reports a net loss of 12.
2 million euros for 2024 (including GRP proceeds) versus a loss of 101.4 million the previous year, as well as a positive adjusted EBITDA of 32.9 million euros, versus a loss of 65.2 million in 2023.

The vaccines company emphasizes that it has achieved its 2024 sales growth (+13% to 163.3 million euros) and revenue targets (+10% to 169.6 million), with sales of Ixiaro/Jespect up 28% to 94.1 million.

Valneva also boasts a solid cash position of 168.3 million euros at the end of 2024, including proceeds from the sale of the Priority Review Voucher (PRV) and the private placement, as well as a 67% reduction in its operating cash consumption.

For 2025, it expects sales to reach €180-190 million, with sales growth expected to reach €170-180 million, generating positive cash flow for all business activities.

Copyright (c) 2025 CercleFinance.com. All rights reserved.